Clinical Trials Browser

Breast Neoplasms, Neoplasms

NCT00086957 2017-02-27

Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer

Phase 1/2 Completed

31 enrolled 10 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00229697 2015-10-05

Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study

Phase 2 Completed

317 enrolled

Breast

Breast Neoplasms

NCT00077025 2014-07-16

Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer

Phase 2 Completed

174 enrolled

Breast

Breast Neoplasms

NCT00057941 2014-05-12

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

Phase 2 Completed

148 enrolled 7 charts

Breast

Breast Neoplasms

NCT00066378 2013-10-24

Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer

Phase 2 Completed

71 enrolled

Breast

Breast Neoplasms

NCT00082667 2013-02-25

Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast

Phase 2 Terminated

1 enrolled

Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT00049062 2013-02-21

Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase 2 Completed

Breast

Breast Neoplasms

NCT00206414 2013-02-05

Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer

Phase 2 Terminated

15 enrolled

Breast

Breast Neoplasms

NCT01732276 2012-12-03

The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer

Phase 2 Unknown

50 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00066339 2012-07-18

Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy

Phase 2 Completed

44 enrolled

Breast

Breast Neoplasms

NCT00252811 2011-01-28

A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer

Phase 2 Withdrawn

60 enrolled

Breast

Breast Neoplasms

NCT00239343 2011-01-27

Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer

Phase 2 Completed

160 enrolled

Breast

Breast Neoplasms

NCT00080743 2009-08-06

Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer

Phase 2 Completed

2 enrolled

Breast

Breast Neoplasms

NCT00234403 2009-04-23

A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer

Phase 2 Completed

60 enrolled

Breast

Breast Neoplasms

NCT00247481 2009-04-23

ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer

Phase 2 Completed

77 enrolled

Breast

Breast Neoplasms

NCT00255463 2009-04-23

Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study

Phase 2 Completed

185 enrolled

Breast

Breast Neoplasms

NCT00637026 2009-04-23

Ph II Early BC Pre-Surgical Biologic Study

Phase 2 Completed

65 enrolled

Breast

Breast Neoplasms

NCT00632723 2009-04-22

IRESSA™ (Gefitinib) in Breast Cancer Patients

Phase 2 Completed

54 enrolled

Breast

Breast Neoplasms

NCT00428896 2008-07-21

A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer

Phase 2 Completed

24 enrolled

Breast

Breast Neoplasms

NCT00052169 2007-12-18

Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer

Phase 2 Completed

33 enrolled

Breast

Breast Neoplasms

NCT00319618 2007-12-18

Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer

Phase 2 Completed

66 enrolled

Breast

Breast Neoplasms

Clinical Trials

Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients

Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer

Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study

Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer

Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast

Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer

Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer

The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer

Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy

A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer

Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer

Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer

A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer

ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer

Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study

Ph II Early BC Pre-Surgical Biologic Study

IRESSA™ (Gefitinib) in Breast Cancer Patients

A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer

Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer

Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer